Vanda Pharmaceuticals (VNDA) Operating Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.97% |
| Dec 31, 2025 | -42.43% |
| Sep 30, 2025 | -43.29% |
| Jun 30, 2025 | -44.03% |
| Mar 31, 2025 | -218.59% |
| Dec 31, 2024 | -34.63% |
| Sep 30, 2024 | -24.76% |
| Jun 30, 2024 | -24.78% |
| Mar 31, 2024 | -34.64% |
| Dec 31, 2023 | -22.65% |
| Sep 30, 2023 | -24.25% |
| Jun 30, 2023 | -22.27% |
| Mar 31, 2023 | -3.88% |
| Dec 31, 2022 | 38.43% |
| Sep 30, 2022 | 22.81% |
| Jun 30, 2022 | 30.60% |
| Mar 31, 2022 | 0.61% |
| Dec 31, 2021 | 72.34% |
| Sep 30, 2021 | 79.37% |
| Jun 30, 2021 | 35.59% |
| Mar 31, 2021 | 23.12% |
| Dec 31, 2020 | 21.99% |
| Sep 30, 2020 | 22.97% |
| Jun 30, 2020 | 29.77% |
| Mar 31, 2020 | 58.61% |
| Dec 31, 2019 | -42.87% |
| Sep 30, 2019 | 56.64% |
| Jun 30, 2019 | 19.71% |
| Mar 31, 2019 | 39.88% |
| Dec 31, 2018 | 25.99% |
| Sep 30, 2018 | 25.78% |
| Jun 30, 2018 | 25.77% |
| Mar 31, 2018 | 20.45% |
| Dec 31, 2017 | 19.67% |
| Sep 30, 2017 | 1.81% |
| Jun 30, 2017 | 24.96% |
| Mar 31, 2017 | 1.01% |
| Dec 31, 2016 | 35.61% |
| Sep 30, 2016 | 27.65% |
| Jun 30, 2016 | -25.92% |
| Mar 31, 2016 | -346.98% |
| Dec 31, 2015 | -83.54% |
| Sep 30, 2015 | -71.51% |
| Jun 30, 2015 | -46.37% |